Kidney Transplantation - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 148 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Kidney Transplantation - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Kidney Transplantation - Pipeline Review, H1 2015', provides an overview of the Kidney Transplantation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Kidney Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Transplantation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kidney Transplantation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Kidney Transplantation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Kidney Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Kidney Transplantation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Kidney Transplantation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Kidney Transplantation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Kidney Transplantation Overview 10
Therapeutics Development 11
Pipeline Products for Kidney Transplantation - Overview 11
Pipeline Products for Kidney Transplantation - Comparative Analysis 12
Kidney Transplantation - Therapeutics under Development by Companies 13
Kidney Transplantation - Therapeutics under Investigation by Universities/Institutes 15
Kidney Transplantation - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Kidney Transplantation - Products under Development by Companies 20
Kidney Transplantation - Products under Investigation by Universities/Institutes 22
Kidney Transplantation - Companies Involved in Therapeutics Development 23
Alexion Pharmaceuticals, Inc. 23
Angion Biomedica Corp. 24
Astellas Pharma Inc. 25
Bio-inRen 26
CSL Limited 27
Digna Biotech, S.L. 28
Effimune SAS 29
GlaxoSmithKline plc 30
Grifols, S.A. 31
Hansa Medical AB 32
Kyowa Hakko Kirin Co., Ltd. 33
Novartis AG 34
Onyx Pharmaceuticals, Inc. 35
Opsona Therapeutics Ltd. 36
Pharmicell Co., Ltd. 37
Pharming Group N.V. 38
Quark Pharmaceuticals, Inc. 39
Shire Plc 40
t-cell Europe GmbH 41
Tolera Therapeutics, Inc. 42
Kidney Transplantation - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
albumin (human) - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AS-2521780 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ASKP-1240 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
BB-3 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
belimumab - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
BRN-1889 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
C1 esterase inhibitor (human) - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
C1 esterase inhibitor (human) - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
C1 esterase inhibitor (recombinant) - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
cardiotrophin-1 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
carfilzomib - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Cell Therapy for Kidney Transplantation - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Cell Therapy for Kidney Transplantation - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
CFZ-533 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
eculizumab - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
EFFI-7H - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
ETR-002 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
FCR-001 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
foralumab - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
FX-06 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
IgG-Degrading Enzyme of Streptococcus pyogenes - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Immucellgram - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
OPN-305 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
QPI-1002 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
T-Cell Therapy for Kidney Transplant - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
TOL-101 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
voclosporin - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Kidney Transplantation - Recent Pipeline Updates 105
Kidney Transplantation - Dormant Projects 135
Kidney Transplantation - Discontinued Products 137
Kidney Transplantation - Product Development Milestones 138
Featured News & Press Releases 138
May 14, 2015: Angion Biomedica Advances BB3 into Pivotal Phase 3 Clinical Trial in Renal Transplant Patients with Delayed Graft Function 138
May 06, 2015: Hansa Medical Establishes a US medical advisory board for IdeS in kidney transplantation 139
Apr 13, 2015: Alexion Announces Presentations at 2015 American Transplant Congress, Including Results from Studies Advancing the Understanding of Eculizumab (Soliris) in Patients Undergoing Kidney Transplant 140
Feb 12, 2015: Hansa Medical develops second-generation IdeS molecules for repeat dosing 141
Feb 05, 2015: Hansa Medical announces cooperation with Cedars-Sinai Medical Center's Comprehensive Transplant Center and US transplantation expert Stanley Jordan 141
Jan 20, 2015: Successful Phase 2 Study of IdeS in Highly Sensitized Dialysis Patients awaiting Kidney Transplantation 142
Jan 07, 2015: Alexion Provides Update on Phase 2 Clinical Trial with Eculizumab in Antibody Mediated Rejection (AMR) in Living-Donor Kidney Transplant Recipients 142
Aug 25, 2014: Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function (DGF) after Kidney Transplantation 143
Aug 18, 2014: The Hansa Medical candidate drug IdeS has enabled successful kidney transplantation 144
Jul 28, 2014: Quark Pharmaceuticals Reports Favorable Results From Phase II Clinical Trial Evaluating Investigational siRNA QPI-1002 145
Appendix 147
Methodology 147
Coverage 147
Secondary Research 147
Primary Research 147
Expert Panel Validation 147
Contact Us 147
Disclaimer 148

List of Tables

Number of Products under Development for Kidney Transplantation, H1 2015 11
Number of Products under Development for Kidney Transplantation - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Comparative Analysis by Unknown Stage Development, H1 2015 19
Products under Development by Companies, H1 2015 20
Products under Development by Companies, H1 2015 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2015 22
Kidney Transplantation - Pipeline by Alexion Pharmaceuticals, Inc., H1 2015 23
Kidney Transplantation - Pipeline by Angion Biomedica Corp., H1 2015 24
Kidney Transplantation - Pipeline by Astellas Pharma Inc., H1 2015 25
Kidney Transplantation - Pipeline by Bio-inRen, H1 2015 26
Kidney Transplantation - Pipeline by CSL Limited, H1 2015 27
Kidney Transplantation - Pipeline by Digna Biotech, S.L., H1 2015 28
Kidney Transplantation - Pipeline by Effimune SAS, H1 2015 29
Kidney Transplantation - Pipeline by GlaxoSmithKline plc, H1 2015 30
Kidney Transplantation - Pipeline by Grifols, S.A., H1 2015 31
Kidney Transplantation - Pipeline by Hansa Medical AB, H1 2015 32
Kidney Transplantation - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 33
Kidney Transplantation - Pipeline by Novartis AG, H1 2015 34
Kidney Transplantation - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 35
Kidney Transplantation - Pipeline by Opsona Therapeutics Ltd., H1 2015 36
Kidney Transplantation - Pipeline by Pharmicell Co., Ltd., H1 2015 37
Kidney Transplantation - Pipeline by Pharming Group N.V., H1 2015 38
Kidney Transplantation - Pipeline by Quark Pharmaceuticals, Inc., H1 2015 39
Kidney Transplantation - Pipeline by Shire Plc, H1 2015 40
Kidney Transplantation - Pipeline by t-cell Europe GmbH, H1 2015 41
Kidney Transplantation - Pipeline by Tolera Therapeutics, Inc., H1 2015 42
Assessment by Monotherapy Products, H1 2015 43
Number of Products by Stage and Target, H1 2015 45
Number of Products by Stage and Mechanism of Action, H1 2015 47
Number of Products by Stage and Route of Administration, H1 2015 49
Number of Products by Stage and Molecule Type, H1 2015 51
Kidney Transplantation Therapeutics - Recent Pipeline Updates, H1 2015 105
Kidney Transplantation - Dormant Projects, H1 2015 135
Kidney Transplantation - Dormant Projects (Contd..1), H1 2015 136
Kidney Transplantation - Discontinued Products, H1 2015 137